BV421 Mouse Anti-Human TIGIT
Multicolor flow cytometric analysis of TIGIT expression on peripheral blood lymphocytes. Whole blood was costained with Alexa Fluor®647 Mouse Anti-Human CD56 (Cat. No. 557711), Alexa Fluor®488 Mouse Anti-Human CD4 (Cat. No. 557695), BUV395 Mouse Anti-Human CD45RO (Cat. No. 564291 or 564292), and either BD Horizon™ BV421 Mouse IgG2b, κ Isotype Control (Cat. No. 562748, Top Plots) or BD OptiBuild™ BV421 Mouse Anti-Human TIGIT (Cat. No. 747844, Bottom Plots) at 0.5 μg/test. After staining, the cells were treated with 1× BD Pharm Lyse™ Lysing Solution (Cat. No. 555899) to remove erythrocytes. Left Plots: The pseudocolor dot plots showing the correlated expression of TIGIT [or Ig Isotype control staining] versus CD56 were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Right Plots: The pseudocolor dot plots showing the coexpression of TIGIT [or Ig Isotype control staining] versus CD45RO were derived from gated viable CD4-positive lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. The above is qualification data only and does not represent a specific OptiBuild™ lot.
BD OptiBuild™ BV421 Mouse Anti-Human TIGIT
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.